Transformative Cardiovascular Risk Management Solutions Extend
Beyond Traditional Sectors to Include Federal and State
Correctional Facilities, Broker and Benefits Organizations, and
Risk Bearing Providers.
Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven
precision cardiovascular medicine company, announced today the
nationwide rollout and a significant expansion of its
groundbreaking HeartRisk™ platform. HeartRisk combines insights
from HIPAA-compliant anonymized and aggregated clinical
cardiovascular data obtained through Cardio Diagnostics’ Epi+Gen
CHD and PrecisionCHD clinical tests, with industry and geographic
data to enable real-time population-level cardiovascular disease
(CVD) risk insights.
This expansion extends the reach of its proprietary data
intelligence platform to correctional facilities, risk-bearing
providers engaged in value-based contracts, and broker and benefits
consultants. The move marks a strategic leap in addressing the
financial and security challenges, such as those associated with
transporting inmates in correctional facilities, of scaling access
to cardiovascular testing across diverse sectors.
"By expanding our HeartRisk™ platform, we're not just innovating
within traditional healthcare sectors but breaking new ground in
diverse markets. From correctional facilities to value-based care
providers and workplace wellness programs to brokerage and benefits
consultants, our precision cardiovascular solutions provide
actionable insights. By coupling data intelligence to
evidence-based and scalable clinical tests, we're enabling these
healthcare stakeholders and their organizations to make data-driven
decisions to address rising healthcare costs and implement more
effective chronic disease management. We're not just advancing
precision medicine; we're ensuring those insights can be leveraged
at the population level for multiple sectors," shared Meesha Dogan,
Ph.D., CEO and Co-Founder of Cardio Diagnostics.
Risk-Bearing Providers and Value-Based Care
Risk-bearing providers, such as Family Medicine Specialists that
receive monthly HeartRisk population data, can better manage their
shared-risk and value-based contracts by identifying and
stratifying at-risk populations, and understanding the drivers of
heart disease, ensuring quality measures and ratings are met. This
leads to benefiting from shared risk contracts while
better-managing patient health.
Family Medicine Specialists' implementation of Cardio
Diagnostics' tests in their patient population with CHD risk
factors demonstrates the first time a risk-bearing provider is
leveraging precision epigenetics-based heart disease technologies
with a population health intelligence tool to optimize risk-sharing
contracts. HeartRisk's ability to aggregate population-level heart
attack risk, the presence of heart disease detection, and
intervention monitoring and management aligns with the financial
incentives of shared-risk contracts.
Empowering Workplace Wellness & Financial Health
The expanded offering equips employers with unparalleled
insights into workforce health trends related not just to
cardiovascular risks but also encapsulating broader wellness
indicators crucial for business resilience and productivity. By
integrating predictive analytics around CVD within comprehensive
workplace wellness initiatives, employers can reduce healthcare
costs significantly while fostering an invigorated workplace
culture centered on health mindfulness.
Enabling Precision-Driven Decision-Making for Employer
Clients
Brokerage and benefits entities play a pivotal role in aligning
coverage plans that articulate both value and efficacy against
chronic conditions like CVD, which are substantial cost centers for
their clientele. The enhanced functionalities within the HeartRisk™
platform allow these entities to offer meticulous plan designs
optimized by granular cumulative data insights, thus ensuring
impactful investments in healthcare portfolios. This includes being
able to guide employer clients on stop-loss insurance decisions,
benefits allocations, and premium and escrow limits using more
real-time aggregated employer CVD risk intelligence data based on
clinical tests for a prospective analysis rather than a
retrospective analysis.
Tackling Healthcare Challenges Behind Bars: A Constitutional
Requirement
Cardiovascular disease is a leading cause of death among
incarcerated individuals. The incarcerated population exhibits
higher rates of cardiovascular risk factors, such as smoking and
hypertension, compared to the general population. Correctional
facilities have a constitutional obligation to care for the health
of incarcerated individuals. This includes the provision of medical
and mental health care, which is complicated by the high prevalence
of chronic diseases, mental health issues, and substance use
disorders among the incarcerated population.
The complexity of providing care in correctional facilities is
exacerbated by resource constraints and the difficulty of providing
specialized care for heart disease without transportation. The
costs and security risks associated with transporting inmates into
healthcare settings and facilities are staggering. Annually, more
than $90 million is spent on transporting inmates to U.S Hospitals
annually. HeartRisk, driven by the adoption of Epi+Gen CHD and
PrecisionCHD via telehealth, is a highly scalable approach for
correctional facilities to obtain heart attack and heart disease
insights.
Impact on Healthcare Costs and Chronic Disease
Management
The expansion of the HeartRisk™ platform is aligned with the
broader trend in healthcare towards prevention and value-based
care. Preventive measures are not only lifesaving but also
economically beneficial, with an estimated return of $6.30 in
savings for every $1 invested. Active strategies for risk factor
reduction, prevention, and treatment of CVD, powered by precision
population analytics, are key to addressing these growing
cardiovascular cost challenges.
About Cardio Diagnostics
Cardio Diagnostics is an artificial intelligence-powered
precision cardiovascular medicine company that makes cardiovascular
disease prevention, detection, and management more accessible,
personalized, and precise. The Company was formed to further
develop and commercialize clinical tests by leveraging a
proprietary Artificial Intelligence (AI)-driven Integrated
Genetic-Epigenetic Engine ("Core Technology") for cardiovascular
disease to become one of the leading medical technology companies
for improving prevention, detection, and treatment of
cardiovascular disease. For more information, please visit
www.cardiodiagnosticsinc.com.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases "will," "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," "goal," or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include but are not limited to, our ability
to successfully execute our growth strategy, changes in laws or
regulations, economic conditions, dependence on management,
dilution to stockholders, lack of capital, the effects of rapid
growth upon the Company and the ability of management to
effectively respond to the growth and demand for products and
services of the Company, newly developing technologies, the
Company's ability to compete, regulatory matters, protection of
technology, the effects of competition and the ability of the
Company to obtain future financing. An extensive list of factors
that can affect future results are discussed in the Current Report
on Form 10-K for the period ended December 31, 2022, and Forms 10-Q
for the periods ended March 31, 2023, and September 30, 2023, under
the heading "Risk Factors" in Part I, Item IA thereof, and other
documents filed from time to time with the Securities and Exchange
Commission. Such factors could materially adversely affect the
Company's financial performance and could cause the Company's
actual results for future periods to differ materially from any
opinions or statements expressed within this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240215818293/en/
Investors: Gene Mannheimer Investor Relations
855-226-9991 investors@cardiodiagnosticsinc.com
Media & Public Relations: Khullani Abdullahi
855-226-9991 pr@cardiodiagnosticsinc.com
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Cardio Diagnostics (NASDAQ:CDIO)
Historical Stock Chart
From Nov 2023 to Nov 2024